glp-1 therapies success rate Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes Association between plausible genetic factors

When patients understand both the metabolic benefits and the potential hepatobiliary risks, they are more likely to engage in proactive symptom reporting

The six-month study showed that patients who stuck to their medication (95% adherence at three months), regularly did strength training, and ate enough protein were more successful at preserving muscle mass

[31] The takeaway is vigilance: any GLP-1 user with diabetes especially on combined therapy with SGLT2 inhibitors, who presents with persistent vomiting or reduced oral intake deserves consideration for EDKA

In adipose tissue, GLP-1 receptors are directly expressed and activation impacts apoptosis and preadipocyte proliferation, as well as fat deposition through regulation of lipolysis, fatty acid oxidation, and adipocyte differentiation